05 February 2020 2 Min Read
Merck spins off assets to focus on main growth drivers: cancer drugs, vaccines
The spin-off is a culmination of the drugmaker’s strategy of concentrating on a few key areas, particularly oncology
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In